4-nitrobenzoate | 14337-48-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-nitrobenzoate
• CAS: 14337-48-5
• 化学式: C₇H₄NO₄
• 分子量: 166.113
• InChiKey: OTLNPYWUJOZPPA-UHFFFAOYSA-M

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  86
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4-nitrobenzoate 以 甲醇 为溶剂， 生成 对硝基苯甲酸
  参考文献：
  名称：

  Ka Values of Weak Organic Acids in Protic Solvents Obtained from Their First Hyperpolarizabilities in Solution

  摘要：

  The first hyperpolarizabilities (beta) of some weak aromatic organic acids have been measured in protic solvents by the hyper-Rayleigh scattering (HRS) technique at low concentrations. The measured hyperpolarizability (beta(m)) varies between the two extreme limits: the hyperpolarizability of the acid form (beta(HA)) at the lower side and that of the basic form (beta(A-)) at the higher side. The degree of dissociation (alpha) of the acid in a solvent is related to the measured hyperpolarizability, beta(m), by the following relationship: beta(m)(2)=(1-alpha)beta(HA)(2)+alpha beta(A-)(2). The calculated beta's including solvent effects in terms of an Onsager field do not reproduce the experimentally measured hyperpolarizabilities. Other solvent-induced effects like hydrogen bonding and van der Waals interactions seem to influence the first hyperpolarizability and, thus, indirectly the extent of dissociation of these weak acids in these protic solvents.

  DOI：

  10.1021/j100051a014
• 作为产物：
  描述：

  4-硝基苯甲酰氯 在 sodium hydroxide 、 重水 、 N,N-二异丙基乙胺 作用下， 以 二氧六环-d8 、 二氯甲烷 为溶剂， 反应 0.67h， 生成 4-nitrobenzoate
  参考文献：
  名称：

  基于7-氮杂双环[2.2.1]庚烷骨架的对金字塔形氮酰胺的碱催化水解的意外耐受性。

  摘要：

  非平面酰胺通常是过渡结构，参与酰胺键的旋转和氮原子的转化，但是已经报道了一些最低限度的非平面酰胺。非平面酰胺通常对水或其他亲核试剂敏感，因此酰胺键容易断裂。在本文中，我们研究了7-氮杂双环[2.2.1]庚烷酰胺的碱催化水解反应的反应性，该反应表明酰胺氮原子呈锥体反应，并且比较了碱催化苯甲酰胺水解的动力学。 7-氮杂双环[2.2.1]庚烷和相关的单环化合物。出乎意料的是，发现基于7-氮杂双环[2.2.1]庚烷骨架的非平面酰胺对碱催化的水解具有抵抗力。计算的吉布斯自由能与该实验结果一致。热校正的贡献（熵项，⁻TΔS‡）很大；熵项（ΔS‡）取大的负值，表明过渡结构中的重要顺序包括溶剂化水分子。

  DOI：

  10.3390/molecules23092363

文献信息

• [EN] FLUOROPHORE COMPOUNDS<br/>[FR] COMPOSÉS FLUOROPHORES
  申请人：VERSITECH LTD

  公开号：WO2009121244A1

  公开（公告）日：2009-10-08

  Provided herein are fluorophore compounds including rhodol and rhodamine compounds which can be used as fluorescent labels and/or fluorogenic probes and methods of making same. Provided also herein are methods that can be used to track, measure, detect, or screen biological species such as protein, DNA, enzyme, antibody, organelle, cell, tissue, drug, hormone, nucleotide, nucleic acid, polysaccharide or lipid in living organisms. Specifically, the methods include the steps of contacting any of the fluorophore compounds, rhodol compounds and rhodamine compounds disclosed herein with the biological species to form one or more fluorescent compounds, and measuring fluorescence properties of the fluorescent compounds. Provided also herein are high-throughput screening fluorescent methods for detecting or screening biological species.

  本文提供了包括罗多尔和罗丹明化合物在内的荧光物质，可用作荧光标记剂和/或荧光探针，并提供了制备这些化合物的方法。本文还提供了可用于跟踪、测量、检测或筛选蛋白质、DNA、酶、抗体、细胞器、细胞、组织、药物、激素、核苷酸、核酸、多糖或脂质等生物种类在活体中的方法。具体而言，这些方法包括将本文披露的任何荧光物质、罗多尔化合物和罗丹明化合物与生物种类接触以形成一个或多个荧光化合物，并测量荧光化合物的荧光特性。本文还提供了用于检测或筛选生物种类的高通量筛选荧光方法。
• SUBSTITUTED HETEROCYCLES AS ANTIVIRAL AGENTS
  申请人：Enanta Pharmaceuticals, Inc.

  公开号：US20190224188A1

  公开（公告）日：2019-07-25

  The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts thereof: which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

  本发明公开了式(I)的化合物及其药学上可接受的盐： 这些化合物抑制由乙型肝炎病毒（HBV）编码的蛋白质或干扰乙型肝炎病毒的生命周期功能，并且还可用作抗病毒剂。本发明还涉及包括上述化合物的药物组合物，用于治疗患有HBV感染的受试者。该发明还涉及通过给予包含本发明化合物的药物组合物来治疗受试者的HBV感染的方法。
• APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS AND METHODS OF USE THEREOF
  申请人：Enanta Pharmaceuticals, Inc.

  公开号：US20200157095A1

  公开（公告）日：2020-05-21

  The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts and esters thereof: which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcohol steatohepatitis disease (NASH).

  本发明公开了化合物的结构式(I)，以及其药学上可接受的盐和酯： 这些化合物抑制凋亡信号调节激酶1（ASK-1），与自身免疫性疾病、神经退行性疾病、炎症性疾病、慢性肾脏疾病、心血管疾病相关。本发明还涉及包含上述化合物的药物组合物，用于治疗患有ASK-1相关疾病的受试者。该发明还涉及通过给予包含本发明化合物的药物组合物来治疗受试者的ASK-1相关疾病的方法。本发明具体涉及治疗与肝脂肪变性相关的ASK-1的方法，包括非酒精性脂肪肝病（NAFLD）和非酒精性脂肪性肝炎病（NASH）。
• Camptothecin derivatives as chemoradiosensitizing agents
  申请人：Yang Li-Xi

  公开号：US20070093432A1

  公开（公告）日：2007-04-26

  Camptothecin-based compounds are useful for treating a neoplasm in mammalian subjects by administering such compound to the subjects in combination with radiotherapy, i.e., the treatment of tumors with radioactive substances or radiation from a source external to the subject. Camptothecin-based compounds are modified by positioning at least one electron-affinic group around the camptothecin structure to enhance their value in combination with radiotherapy. New Camptothecin-based compounds are disclosed that are useful for treating cancer by administering the novel compounds alone or in combination with radiotherapy.

  基于紫杉醇的化合物通过将该化合物与放射疗法结合在一起向哺乳动物体内施用，对治疗肿瘤具有益处，即使用放射性物质或来自主体外部源的辐射治疗肿瘤。通过在紫杉醇结构周围定位至少一个电子亲和基团来改性基于紫杉醇的化合物，以增强它们与放射疗法结合的价值。还披露了新的基于紫杉醇的化合物，可通过单独或与放射疗法结合使用这些新化合物来治疗癌症。
• Novel heterocyclic compounds, preparation process and intermediates, and use as medicaments, in particular as B-lactamase inhibitors and antibacterials
  申请人：AVENTIS PHARMA S.A.

  公开号：US20040097490A1

  公开（公告）日：2004-05-20

  The invention relates to novel heterocyclic compounds of general formula (I) and to their salts with a base or an acid: 1 The invention also relates to processes and to intermediates for the preparation of these compounds, and to their use as medicaments, in particular as antibacterials and &bgr;-lactamase inhibitors.

  这项发明涉及一般式(I)的新型杂环化合物及其与碱或酸形成的盐： 该发明还涉及制备这些化合物的过程和中间体，以及它们作为药物的用途，特别是作为抗菌药物和β-内酰胺酶抑制剂。